Latest & greatest articles for influenza

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on influenza or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on influenza and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for influenza

81. Influenza Virological Surveillance in the WHO African Region: Epidemiological Week 43, October 23 to 29

Influenza Virological Surveillance in the WHO African Region: Epidemiological Week 43, October 23 to 29 WHO IRIS: Influenza Virological Surveillance in the WHO African Region: Epidemiological Week 43, October 23 to 29 Browse Related links Files in This Item: File Description Size Format 765.86 kB Adobe PDF Title: Influenza Virological Surveillance in the WHO African Region: Epidemiological Week 43, October 23 to 29 Authors: Issue Date: 2017 Publisher: World Health Organization. Regional Office (...) for Africa Journal: Influenza Virological Surveillance in the WHO African Region, 3 (43): 1-3 Place of publication: Brazzaville Language: English Description: 3 p. Subject: URI: Appears in Collections: Items in WHO IRIS are protected by copyright, with all rights reserved, unless otherwise indicated. |

WHO2017

82. Influenza Virological Surveillance in the WHO African Region: Epidemiological Week 42, October 16 to 22

Influenza Virological Surveillance in the WHO African Region: Epidemiological Week 42, October 16 to 22 WHO IRIS: Influenza Virological Surveillance in the WHO African Region: Epidemiological Week 42, October 16 to 22 Browse Related links Files in This Item: File Description Size Format 764.62 kB Adobe PDF Title: Influenza Virological Surveillance in the WHO African Region: Epidemiological Week 42, October 16 to 22 Authors: Issue Date: 2017 Publisher: World Health Organization. Regional Office (...) for Africa Journal: Influenza Virological Surveillance in the WHO African Region, 3 (42): 1-3 Place of publication: Brazzaville Language: English Description: 3 p. Subject: URI: Appears in Collections: Items in WHO IRIS are protected by copyright, with all rights reserved, unless otherwise indicated. |

WHO2017

83. Influenza Virological Surveillance in the WHO African Region: Epidemiological Week 29: July 10 to 16 2017

Influenza Virological Surveillance in the WHO African Region: Epidemiological Week 29: July 10 to 16 2017 WHO IRIS: Influenza Virological Surveillance in the WHO African Region: Epidemiological Week 29: July 10 to 16 2017 Browse Related links Files in This Item: File Description Size Format 648.25 kB Adobe PDF Title: Influenza Virological Surveillance in the WHO African Region: Epidemiological Week 29: July 10 to 16 2017 Authors: Issue Date: 2017 Publisher: World Health Organization. Regional (...) Office for Africa Journal: Influenza Virological Surveillance, 3 (29): 1-3 Place of publication: Brazzaville Language: English Description: 3 p. Keywords: Influenza A/H1N1pdm09 Subject: URI: Appears in Collections: Items in WHO IRIS are protected by copyright, with all rights reserved, unless otherwise indicated. |

WHO2017

84. Influenza Virological Surveillance in the WHO African Region

Influenza Virological Surveillance in the WHO African Region WHO IRIS: Influenza Virological Surveillance in the WHO African Region Browse Related links Files in This Item: File Description Size Format 651.67 kB Adobe PDF Title: Influenza Virological Surveillance in the WHO African Region Authors: Issue Date: 2017 Publisher: World Health Organization.Regional Office for Africa Journal: Influenza Virological Surveillance, 3 (34) Place of publication: Brazzaville Language: English Description: 3 (...) p. Keywords: Influenza A/H1N1pdm09 Subject: URI: Appears in Collections: Items in WHO IRIS are protected by copyright, with all rights reserved, unless otherwise indicated. |

WHO2017

85. Isolation and phylogenetic characterization of haemagglutinin and neuraminidase genes of H9N2 low pathogenicity avian influenza virus isolated from commercial layers in India

Isolation and phylogenetic characterization of haemagglutinin and neuraminidase genes of H9N2 low pathogenicity avian influenza virus isolated from commercial layers in India 28004018 2018 11 13 2347-3584 27 4 2016 Dec Virusdisease Virusdisease Isolation and phylogenetic characterization of haemagglutinin and neuraminidase genes of H9N2 low pathogenicity avian influenza virus isolated from commercial layers in India. 382-386 10.1007/s13337-016-0350-8 Avian influenza is a highly infectious (...) and dynamically evolving disease of birds causing high morbidity and mortality. It is caused by avian influenza virus (AIV) that belongs to the family Orthomyxoviridae. Two types of AIV have been described based on their pathogenicity viz. highly pathogenic avian influenza virus that causes severe disease with high mortality and low pathogenic avian influenza virus (LPAI) that generally causes asymptomatic infection or a mild disease. The H9N2 subtype is the widely circulated LPAI type in the world. The H9N2

Virusdisease2016 Full Text: Link to full Text with Trip Pro

86. Knowledge of H7N9 avian influenza and intention to adopt preventive behaviours among Chinese poultry farmers: a cross-sectional study.

Knowledge of H7N9 avian influenza and intention to adopt preventive behaviours among Chinese poultry farmers: a cross-sectional study. BACKGROUND: Poultry farmers are at high risk of H7N9 avian influenza infection. H7N9 influenza-related knowledge is the precondition motivating poultry farmers to adopt preventive behaviours against H7N9 infection. This study aimed to examine what elements of the knowledge were associated with poultry farmers' protection intention using the protection motivation (...) theory (PMT). METHODS: In this cross-sectional study, using stratified random sampling method, we recruited poultry farmers from 36 villages of three cities (Suqian, Nantong, and Zhenjiang city) representing the northern, central, and southern Jiangsu Province, one of the major provinces affected by H7N9 outbreaks. We assessed H7N9 influenza-related knowledge with 25 dichotomous questions (ask for 'know/don't know' responses). Each element of PMT (perceived severity and vulnerability of H7N9

Lancet2016

87. Risk for Congenital Malformation With H1N1 Influenza Vaccine: A Cohort Study With Sibling Analysis.

Risk for Congenital Malformation With H1N1 Influenza Vaccine: A Cohort Study With Sibling Analysis. Background: Earlier studies reporting varying risk estimates for congenital malformation in offspring of mothers undergoing vaccination against H1N1 influenza during pregnancy did not consider the potential role of confounding by familial (genetic and shared environmental) factors. Objective: To evaluate an association between maternal H1N1 vaccination during pregnancy and offspring malformation (...) , with familial factors taken into account. Design: Population-based prospective study. Setting: Sweden. Participants: Liveborn offspring born between 1 October 2009 and 1 October 2011 to mothers receiving monovalent AS03-adjuvanted H1N1 influenza vaccine (Pandemrix [GlaxoSmithKline]) during pregnancy. A total of 40 983 offspring were prenatally exposed to the vaccine, 14 385 were exposed within the first trimester (14 weeks), and 7502 were exposed during the first 8 weeks of pregnancy. Exposed offspring were

Annals of Internal Medicine2016

88. Influenza infection modulates vesicular trafficking and induces Golgi complex disruption

Influenza infection modulates vesicular trafficking and induces Golgi complex disruption 28004015 2018 11 13 2347-3584 27 4 2016 Dec Virusdisease Virusdisease Influenza infection modulates vesicular trafficking and induces Golgi complex disruption. 357-368 10.1007/s13337-016-0347-3 Influenza A virus (IFV) replicates its genome in the nucleus of infected cells and uses the cellular protein transport system for genome trafficking from the nucleus to the plasma membrane. However, many details (...) out complementary studies to determine the effect of IFV on intracellular membranes. Inhibition of the CRM1 and TAP-P15 nuclear transport pathways by DRB and LB blocked completely the export of virus. Inhibition of vesicular trafficking by BFA, NOC, and ZWEHD also affected influenza infection. Interestingly, IFV infection induced fragmentation of the Golgi complex resulting in diffuse distribution of large and small vesicles throughout the cytoplasm. Live-cell microscopy revealed expansion

Virusdisease2016 Full Text: Link to full Text with Trip Pro

89. Acute posterior multifocal placoid pigment epitheliopathy and granulomatous uveitis following influenza vaccination

Acute posterior multifocal placoid pigment epitheliopathy and granulomatous uveitis following influenza vaccination 29503928 2018 11 14 2451-9936 4 2016 Dec American journal of ophthalmology case reports Am J Ophthalmol Case Rep Acute posterior multifocal placoid pigment epitheliopathy and granulomatous uveitis following influenza vaccination. 60-63 10.1016/j.ajoc.2016.08.008 To report a case of acute placoid multifocal posterior pigment epitheliopathy (APMPPE) following influenza vaccination (...) . The patient exhibited granulomatous uveitis during the recovery phase. A woman in her thirties developed flu-like symptoms seven days after receiving an influenza vaccination. Approximately 2 weeks later, the patient reported with conjunctival injection, blurred vision, and pain in her left eye. She was examined in our clinic, and the best-corrected visual acuity was 20/15 OD and 20/20 OS. Multiple whitish spots were observed bilaterally in the deep retinal layer along with edema of the left optic disc

American journal of ophthalmology case reports2016 Full Text: Link to full Text with Trip Pro

90. Seroconversion and immunogenicity evaluation of seasonal influenza vaccine in mice model

Seroconversion and immunogenicity evaluation of seasonal influenza vaccine in mice model 28466037 2018 11 13 2347-3584 27 3 2016 Sep Virusdisease Virusdisease Seroconversion and immunogenicity evaluation of seasonal influenza vaccine in mice model. 260-265 10.1007/s13337-016-0336-6 Influenza virus is epidemiologically very important due to the antigenic variations occurring in it. In present study isolation and identification of influenza virus was attempted from Kasauli and adjoining areas. 71 (...) clinical samples i.e. throat washings were processed and inoculated into the eggs for virus isolation. The isolated strains of H3N2, H1N1 and Influenza B were identified, purified and passaged in eggs. The harvested virus was inactivated by 0.03 % formalin and three formulations of crude, inactivated, whole virus monovalent vaccine for H3N2, H1N1 and influenza B as well as a trivalent vaccine was prepared. The immunogenicity study of the vaccine was performed in the mouse model by using varying

Virusdisease2016 Full Text: Link to full Text with Trip Pro

91. Live Attenuated Versus Inactivated Influenza Vaccine in Hutterite Children: A Cluster Randomized Blinded Trial.

Live Attenuated Versus Inactivated Influenza Vaccine in Hutterite Children: A Cluster Randomized Blinded Trial. Background: Whether vaccinating children with intranasal live attenuated influenza vaccine (LAIV) is more effective than inactivated influenza vaccine (IIV) in providing both direct protection in vaccinated persons and herd protection in unvaccinated persons is uncertain. Hutterite colonies, where members live in close-knit, small rural communities in which influenza virus infection (...) regularly occurs, offer an opportunity to address this question. Objective: To determine whether vaccinating children and adolescents with LAIV provides better community protection than IIV. Design: A cluster randomized blinded trial conducted between October 2012 and May 2015 over 3 influenza seasons. (ClinicalTrials.gov: NCT01653015 ). Setting: 52 Hutterite colonies in Alberta and Saskatchewan, Canada. Participants: 1186 Canadian children and adolescents aged 36 months to 15 years who received

Annals of Internal Medicine2016

92. Differential proteomic analysis of respiratory samples from patients suffering from influenza

Differential proteomic analysis of respiratory samples from patients suffering from influenza 28466033 2018 11 13 2347-3584 27 3 2016 Sep Virusdisease Virusdisease Differential proteomic analysis of respiratory samples from patients suffering from influenza. 226-233 10.1007/s13337-016-0332-x The exact molecular pathways involved in the pathogenesis of influenza are yet unclear. In the present study we investigated the upper respiratory proteome in influenza patients. 200 nasal and throat swab (...) samples were collected from patients suffering from acute respiratory illness. These samples were confirmed for influenza pandemic A/H1N1/2009 and influenza type B using qRT-PCR. 10 similar swabs were collected from healthy individuals and were used as controls. Proteins were extracted from the cell pellets and were subjected to 2-D gel electrophoresis. The differentially expressed proteins were identified using MALDI-TOF. Identified proteins were classified into different functional groups based

Virusdisease2016 Full Text: Link to full Text with Trip Pro

93. Lung epithelial GM-CSF improves host defense function and epithelial repair in influenza virus pneumonia—a new therapeutic strategy?

Lung epithelial GM-CSF improves host defense function and epithelial repair in influenza virus pneumonia—a new therapeutic strategy? 27480877 2016 08 02 2018 11 13 2194-7791 3 1 2016 Dec Molecular and cellular pediatrics Mol Cell Pediatr Lung epithelial GM-CSF improves host defense function and epithelial repair in influenza virus pneumonia-a new therapeutic strategy? 29 10.1186/s40348-016-0055-5 Influenza viruses (IVs) circulate seasonally and are a common cause of respiratory infections (...) . 2002 Jul 15;166(2):138-43 12119223 Curr Opin Virol. 2012 Jun;2(3):233-41 22608464 Am J Physiol Lung Cell Mol Physiol. 2015 Jun 1;308(11):L1178-88 26033355 J Immunol. 2004 Nov 15;173(10):6384-92 15528378 AEC ARDS GM-CSF Influenza Pneumonia Therapy 2016 05 02 2016 07 15 2016 8 3 6 0 2016 8 3 6 0 2016 8 3 6 1 ppublish 27480877 10.1186/s40348-016-0055-5 10.1186/s40348-016-0055-5 PMC4969252

Molecular and cellular pediatrics2016 Full Text: Link to full Text with Trip Pro

94. Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data

Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data Journals Library Journals Library An error has occurred in processing the XML document An error has occurred in processing the XML document An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from

NIHR HTA programme2016

96. Seasonal Influenza Infections and Cardiovascular Disease Mortality

Seasonal Influenza Infections and Cardiovascular Disease Mortality 27438105 2018 06 26 2018 11 13 2380-6591 1 3 2016 06 01 JAMA cardiology JAMA Cardiol Seasonal Influenza Infections and Cardiovascular Disease Mortality. 274-81 10.1001/jamacardio.2016.0433 Cardiovascular deaths and influenza epidemics peak during winter in temperate regions. To quantify the temporal association between population increases in seasonal influenza infections and mortality due to cardiovascular causes and to test (...) if influenza incidence indicators are predictive of cardiovascular mortality during the influenza season. Time-series analysis of vital statistics records and emergency department visits in New York City, among cardiovascular deaths that occurred during influenza seasons between January 1, 2006, and December 31, 2012. The 2009 novel influenza A(H1N1) pandemic period was excluded from temporal analyses. Emergency department visits for influenza-like illness, grouped by age (≥0 years and ≥65 years

JAMA cardiology2016 Full Text: Link to full Text with Trip Pro

97. Oseltamivir (Tamiflu) - for the treatment of infants less than 1 year of age including full term neonates who present with symptoms typical of influenza

Oseltamivir (Tamiflu) - for the treatment of infants less than 1 year of age including full term neonates who present with symptoms typical of influenza %PDF-1.5 %���� 84 0 obj > endobj 102 0 obj >/Filter/FlateDecode/ID[ ]/Index[84 36]/Info 83 0 R/Length 89/Prev 200276/Root 85 0 R/Size 120/Type/XRef/W[1 2 1]>>stream h�bbd``b`� $���j �� � $X�@�c@��DT��; B$a $�"Aڔ@D��b��Ü L� ��,F*�g|0�* : endstream endobj startxref 0 %%EOF 119 0 obj >stream h�b`````jf_CP#�0p4 � @1C�����9L��4h]������AN@C��P�� �i

All Wales Medicines Strategy Group2016

98. Safety of Seasonal Influenza Vaccination in Hospitalized Surgical Patients: A Cohort Study.

Safety of Seasonal Influenza Vaccination in Hospitalized Surgical Patients: A Cohort Study. BACKGROUND: Despite recommendations to vaccinate surgical inpatients against influenza, vaccination rates remain low in this population, due in part to concerns about potential negative effects on postsurgical care. OBJECTIVE: To evaluate whether influenza vaccination in the perioperative period increases health care utilization and evaluations for postsurgical infection after discharge. DESIGN (...) : Retrospective cohort study. SETTING: Members of Kaiser Permanente Southern California. PARTICIPANTS: Patients aged 6 months or older who had inpatient surgery with admission and discharge between 1 September and 31 March from 2010 to 2013. MEASUREMENTS: All influenza vaccinations administered between 1 August and 30 April in the 2010-2011, 2011-2012, and 2012-2013 influenza seasons. Outcomes included rates of outpatient visits, readmission, emergency department (ED) visits, fever (temperature ≥38.0 °C

Annals of Internal Medicine2016

99. Recommended composition of influenza virus vaccines for use in the 2016–2017 northern hemisphere influenza season = Composition recommandée pour les vaccins antigrippaux devant être utilisés pendant la saison grippale 2016-2017 dans l’hémisphère Nord

Recommended composition of influenza virus vaccines for use in the 2016–2017 northern hemisphere influenza season = Composition recommandée pour les vaccins antigrippaux devant être utilisés pendant la saison grippale 2016-2017 dans l’hémisphère Nord WHO IRIS: Recommended composition of influenza virus vaccines for use in the 2016–2017 northern hemisphere influenza season = Composition recommandée pour les vaccins antigrippaux devant être utilisés pendant la saison grippale 2016-2017 dans (...) l’hémisphère Nord Browse Related links Files in This Item: File Description Size Format 2.03 MB Adobe PDF Title: Recommended composition of influenza virus vaccines for use in the 2016–2017 northern hemisphere influenza season = Composition recommandée pour les vaccins antigrippaux devant être utilisés pendant la saison grippale 2016-2017 dans l’hémisphère Nord Authors: Issue Date: 11-Mar-2016 Publisher: World Health Organization = Organisation mondiale de la Sant Journal: Weekly Epidemiological Record

WHO2016

100. Oseltamivir (Tamiflu) - Treatment of influenza in children aged <1 year including full term neonates

Oseltamivir (Tamiflu) - Treatment of influenza in children aged <1 year including full term neonates Published 07 March 2016 Product Update: oseltamivir 30mg, 45mg, 75mg capsules and 6mg/mL powder for oral suspension (Tamiflu ® ) SMC No. (1127/16) Roche Products Limited 05 February 2016 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice (...) is summarised as follows: ADVICE: following an abbreviated submission oseltamivir (Tamiflu ® ) is accepted for use within NHS Scotland. Indication under review: Treatment of influenza in children aged <1 year including full term neonates who present with symptoms typical of influenza, when influenza virus is circulating in the community. Efficacy has been demonstrated when treatment is initiated within two days of first onset of symptoms. Oseltamivir is listed in the British National Formulary for Children

Scottish Medicines Consortium2016